These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 19299892)
21. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Bravo EL Curr Hypertens Rep; 2003 Apr; 5(2):122-5. PubMed ID: 12642011 [TBL] [Abstract][Full Text] [Related]
22. Aldosterone, organ damage and dietary salt. Catena C; Colussi G; Sechi LA Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):922-8. PubMed ID: 23803228 [TBL] [Abstract][Full Text] [Related]
23. Aldosterone blockade in CKD: emphasis on pharmacology. Schwenk MH; Hirsch JS; Bomback AS Adv Chronic Kidney Dis; 2015 Mar; 22(2):123-32. PubMed ID: 25704349 [TBL] [Abstract][Full Text] [Related]
24. Antihypertensive therapy: role of aldosterone antagonists. Grandi AM Curr Pharm Des; 2005; 11(17):2235-42. PubMed ID: 16026292 [TBL] [Abstract][Full Text] [Related]
25. Aldosterone's mechanism of action: roles of lysine-specific demethylase 1, caveolin and striatin. Baudrand R; Pojoga LH; Romero JR; Williams GH Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):32-7. PubMed ID: 24275769 [TBL] [Abstract][Full Text] [Related]
26. [Mineralocorticoid receptor antagonists in chronic kidney disease - pros and cons]. Jędras M; Filipowicz E Wiad Lek; 2017; 70(6 pt 2):1205-1208. PubMed ID: 29533915 [TBL] [Abstract][Full Text] [Related]
27. The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker. Gamliel-Lazarovich A; Raz-Pasteur A; Coleman R; Keidar S Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1086-92. PubMed ID: 23524523 [TBL] [Abstract][Full Text] [Related]
28. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Nagase M Clin Exp Nephrol; 2010 Aug; 14(4):303-14. PubMed ID: 20533072 [TBL] [Abstract][Full Text] [Related]
29. Aldosterone and diabetic kidney disease. Kang YS; Cha DR Curr Diab Rep; 2009 Dec; 9(6):453-9. PubMed ID: 19954691 [TBL] [Abstract][Full Text] [Related]
30. [Antifibrotic renal role of mineralcorticoid receptor antagonists]. Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464 [TBL] [Abstract][Full Text] [Related]
31. Role of mineralocorticoid receptor in insulin resistance. Garg R; Adler GK Curr Opin Endocrinol Diabetes Obes; 2012 Jun; 19(3):168-75. PubMed ID: 22499218 [TBL] [Abstract][Full Text] [Related]
32. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. Nagase M; Yoshida S; Shibata S; Nagase T; Gotoda T; Ando K; Fujita T J Am Soc Nephrol; 2006 Dec; 17(12):3438-46. PubMed ID: 17082236 [TBL] [Abstract][Full Text] [Related]
33. Blocking aldosterone in heart failure. Shafiq MM; Miller AB Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity. Sun QL; Li M; Rui HL; Chen YP J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):301-10. PubMed ID: 25500744 [TBL] [Abstract][Full Text] [Related]
35. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Gros R; Ding Q; Liu B; Chorazyczewski J; Feldman RD Am J Physiol Cell Physiol; 2013 Mar; 304(6):C532-40. PubMed ID: 23283935 [TBL] [Abstract][Full Text] [Related]
36. The pathophysiology of aldosterone in the cardiovascular system. Rocha R; Funder JW Ann N Y Acad Sci; 2002 Sep; 970():89-100. PubMed ID: 12381544 [TBL] [Abstract][Full Text] [Related]
37. Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension. Gray Z; Tu W; Chertow GM; Bhalla V Am J Physiol Renal Physiol; 2021 Mar; 320(3):F325-F335. PubMed ID: 33491565 [TBL] [Abstract][Full Text] [Related]
38. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775 [TBL] [Abstract][Full Text] [Related]
39. Obesity, hypertension and aldosterone: is leptin the link? Xie D; Bollag WB J Endocrinol; 2016 Jul; 230(1):F7-F11. PubMed ID: 27252389 [TBL] [Abstract][Full Text] [Related]
40. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. Packer M; Kitzman DW JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]